Cytokinetics Files 8-K on Financials

Ticker: CYTK · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1061983

Cytokinetics Inc 8-K Filing Summary
FieldDetail
CompanyCytokinetics Inc (CYTK)
Form Type8-K
Filed DateAug 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Cytokinetics dropped an 8-K on Aug 8th detailing their financials. Check it out.

AI Summary

Cytokinetics, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial performance and operational status. The company is based in South San Francisco, California.

Why It Matters

This filing provides investors with crucial, up-to-date information on Cytokinetics' financial health and operational performance, which can influence investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not appear to contain any new or unusual risk factors.

Key Players & Entities

  • Cytokinetics, Inc. (company) — Registrant
  • August 08, 2024 (date) — Date of earliest event reported
  • South San Francisco, California (location) — Principal Executive Offices
  • 350 Oyster Point Boulevard (address) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Cytokinetics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on August 08, 2024.

Where are Cytokinetics, Inc.'s principal executive offices located?

Cytokinetics, Inc.'s principal executive offices are located at 350 Oyster Point Boulevard, South San Francisco, California, 94080.

What is Cytokinetics, Inc.'s telephone number?

Cytokinetics, Inc.'s telephone number, including area code, is (650) 624-3000.

What is the Standard Industrial Classification code for Cytokinetics, Inc.?

The Standard Industrial Classification code for Cytokinetics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-08-08 16:01:12

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 8, 2024, Cytokinetics, Incorporated announced its financial results for the second quarter ended June 30, 2024. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02 and under Exhibit 99.1 shall not be considered "filed" under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) 99.1 Press Release dated August 8, 2024 104 The cover page of this report has been formatted in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: August 8, 2024 By: /s/ John O. Faurescu John O. Faurescu, Esq., Vice President, Associate General Counsel & Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.